Prior studies have demonstrated patients with human epidermal growth factor receptor 2 positive (HER2+) and triple-negative breast cancer (TNBC) have an increased risk of developing brain metastases [4,5,7]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.